Literature DB >> 32271999

Clinical value of multiorgan damage in hypertensive crises: A prospective follow-up study.

Hongkun Ma1, Mengdi Jiang1, Zongjie Fu1, Zhiyu Wang1, Pingyan Shen1, Hao Shi1, Xiaobei Feng1, Yongxi Chen1, Xiaoyi Ding2, Zhiyuan Wu2, Wen Zhang1.   

Abstract

Hypertensive crises are associated with high rates of target organ complications and poor outcomes. A recent shift from the definition of malignant hypertension to hypertension-multiorgan damage (MOD) contributes to the diagnosis and management of hypertensive crises. Here, we prospectively included 166 adult (≥18 years old) patients with hypertensive crises (blood pressure >180/120 mm Hg). Target organs and causes of hypertension were assessed. Patients who were diagnosed with malignant hypertensive retinopathy, the absence of malignant hypertensive retinopathy but the presence of damage to at least 3 organs, and the absence of both retinopathy and MOD were classified as the malignant hypertension (n = 48), hypertension-MOD (n = 42), and hypertension without MOD (n = 76) groups, respectively. Patients were followed to evaluate renal and cardiovascular prognoses. At baseline, patients with malignant hypertension had worse renal function, higher level of albuminuria, and more severe microvascular damage than those with hypertension-MOD. Both had similar proportions of malignant arteriolar nephrosclerosis (83% vs 64%), left ventricular hypertrophy (90% vs 88%), abnormal repolarization (71% vs 60%), and left ventricular dysfunction (12% vs 21%). At the twenty months of follow-up, both the malignant hypertension and hypertension-MOD groups had similar blood pressure control rates and proteinuria. Both groups had worse renal outcomes than the hypertension without MOD group (P = .002). Patients with hypertension-MOD (HR = 0.67, [95% CI: 0.30-1.46], P = .31) had similar renal event-free survival than patients with MHT after adjustments of age, sex, blood pressure, and proteinuria control. These results suggest that in hypertensive crises, both malignant hypertension and hypertension-MOD have impact on adverse renal outcomes.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  hypertensive crises; hypertensive emergency; malignant hypertension; outcome; target organ

Mesh:

Substances:

Year:  2020        PMID: 32271999      PMCID: PMC8029737          DOI: 10.1111/jch.13848

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  42 in total

1.  The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension.

Authors:  Bert-Jan H van den Born; Richard P Koopmans; Gert A van Montfrans
Journal:  Am J Hypertens       Date:  2007-08       Impact factor: 2.689

Review 2.  (2) Classification and diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

3.  Lack of difference between malignant and accelerated hypertension.

Authors:  M E Ahmed; J M Walker; D G Beevers; M Beevers
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

4.  Some different types of essential hypertension: their course and prognosis.

Authors:  N M Keith; H P Wagener; N W Barker
Journal:  Am J Med Sci       Date:  1974-12       Impact factor: 2.378

5.  Prognostic factors in malignant hypertension selected by multivariate analysis.

Authors:  C Guerin; F Berthoux
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

6.  Malignant hypertension complicated by acute renal failure.

Authors:  Xiao Li; Wen Zhang; Hong Ren; Xiaoxia Pan; Nan Chen
Journal:  BMJ Case Rep       Date:  2009-06-15

Review 7.  Hypertensive crisis.

Authors:  Maria Alexandra Rodriguez; Siva K Kumar; Matthew De Caro
Journal:  Cardiol Rev       Date:  2010 Mar-Apr       Impact factor: 2.644

8.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

9.  Morbidity and mortality risk among patients with screening-detected severe hypertension in the Malmö Preventive Project.

Authors:  Christina Westerdahl; Bengt Zöller; Eren Arslan; Serap Erdine; Peter M Nilsson
Journal:  J Hypertens       Date:  2014-12       Impact factor: 4.844

Review 10.  ESC Council on hypertension position document on the management of hypertensive emergencies.

Authors:  Bert-Jan H van den Born; Gregory Y H Lip; Jana Brguljan-Hitij; Antoine Cremer; Julian Segura; Enrique Morales; Felix Mahfoud; Fouad Amraoui; Alexandre Persu; Thomas Kahan; Enrico Agabiti Rosei; Giovanni de Simone; Philippe Gosse; Bryan Williams
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2019-01-01
View more
  2 in total

1.  The potential role of complement alternative pathway activation in hypertensive renal damage.

Authors:  Chongjian Wang; Zhiyu Wang; Wen Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-27

2.  Clinical value of multiorgan damage in hypertensive crises: A prospective follow-up study.

Authors:  Hongkun Ma; Mengdi Jiang; Zongjie Fu; Zhiyu Wang; Pingyan Shen; Hao Shi; Xiaobei Feng; Yongxi Chen; Xiaoyi Ding; Zhiyuan Wu; Wen Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-04-09       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.